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Abstract 
The Shenandoah Valley of Virginia is a major poultry growing region in the United States, 
leading to a strong interest in controlling poultry zoonotic pathogens in order to prevent 
economic losses and transmission to humans. Bordetella avium, a Gram negative bacterium, is 
the causative agent of the upper respiratory illness, bordetellosis, in turkeys. An existing 
bordetellosis vaccine decreases severity of the disease but does not limit infection or 
transmission. An improved vaccine for bordetellosis is needed for better efficacy. Our research 
involves developing B. avium as a universal poultry live vaccine platform that will protect 
against bordetellosis and also serve to express foreign antigens. B. avium is hypothesized to have 
the ability to stably express foreign antigens, such as those from important poultry pathogens as 
Campylobacter jejuni, Clostridium perfringens, and Hemorrhagic enteritis virus (HEV), and 
produce a strong immune response to multiple pathogens following intranasal vaccination. The 
gene encoding Baa1, an autotransporter involved in host colonization in B. avium but shown to 
be non-essential, was selected as the location for heterologous genes, to produce an attenuated B. 
avium strain and express the foreign antigens at the cell surface. The potential vaccine delivery 
plasmid design consisted of the plasmid pBBR1-MCS, a broad host range plasmid, into which 
the Baa1 autotransporter was inserted with the foreign antigen of interest replacing the passenger 
domain of the autotransporter gene. Antigens from C. jejuni, such as a flagellin protein and an 
amino acid binding protein, known to elicit immune responses in poultry have been cloned into 
the passenger domain of the autotransporter gene to form the plasmid construct in the E. coli 
plasmid pCR2.1. After moving the construct into pBBR1-MCS, the expression will be tested in 
B. avium. Success of these efforts will allow this vaccine platform to be used for the delivery of 
any number of foreign antigens and response to pathogen threats.  
6 
Introduction 
 Bordetella avium is a Gram negative bacterium that is responsible as the causative agent of 
bordetellosis in turkeys. Bordetellosis is an upper respiratory tract disease in which the bacterium 
colonizes on the ciliated cells of tracheal epithelium (1). The disease primarily occurs in 2-3 
week old poults and is characterized by mucus accumulation in the trachea and nares, depression, 
weight loss, and sneezing and coughing called “snicking” (1). The Malformation of tracheal 
rings can lead to tracheal collapse and suffocation (1). Other species of Bordetella, including B. 
pertussis and B. bronchiseptica, show preferential binding to ciliated tracheal epithelial cells, 
contributing to signs of bordetellosis in their respective hosts (1).  
 Morbidity in young turkeys is high due to secondary infections by Escherichia coli. This 
causes several million dollars in losses to the poultry industry each year (2). The Shenandoah 
Valley of Virginia is a major poultry region in the USA, leading to a strong interest in controlling 
zoonotic pathogens in poultry, including B. avium, to prevent economic losses and transmission 
to humans. Current treatments do not effectively manage bordetellosis (2). An existing 
bordetellosis vaccine in very low usage in the field, as reported by veterinarians in the region, 
decreases severity of the disease; however, it does not limit infection or spread. Thus, a better 
vaccine for bordetellosis is needed. The current vaccine, however, demonstrates that live 
attenuated B. avium vaccines can be used in highly susceptible poultry populations without 
serious harm. The delivery of heterologous antigens from bacteria important to human health 
could easily be administered through intranasal/ocular vaccination or in drinking water of young 
poults (3).  
 Using bioinformatics and literature searching, genes for two outer membrane proteins from 
B. avium, HagB and Baa1, were explored as possible locations for the insertion of heterologous 
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genes from other poultry pathogens, both to produce an attenuated B. avium strain and express 
foreign antigens at the cell surface. Unknown issues were raised in previous research about the 
lack of understanding of the secretion mechanism of HagB, a hemagglutinin (4), and led to the 
focus on Baa1, an autotransporter involved in host colonization (5).  
 Live vaccines use naturally occurring bacterial transport systems to deliver antigens to the 
surface. Autotransporters are an example of effective delivery systems and allow for protein 
stability and ease of detection of the antigen in the live vaccine (6). An autotransporter is a 
protein using a secretion system consisting of an N-terminal signal sequence to target proteins to 
the Sec apparatus, a passenger domain exposed to the bacterial surface (7), and a conserved C-
terminal pore-forming domain through which the N-terminal passenger domain is exported (8). 
The N-terminal passenger domain is translocated out of the membrane into the extracellular 
environment and can be cleaved to be released from the cell surface (7) (Figure 1). Baa1 
specifically acts as a type V secretion system. Autotransporters are able to perform virulence 
related functions; their virulence factor proteins make them ideal candidates for subunit vaccines, 
using the antigen to stimulate the immune system, due to their surface localization and high 
antigenicity (5). 
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Figure 1. Model of the translocation of the modified Baa1 autotransporter through the cell 
membrane. The signal sequence (red) targets the protein to the Sec apparatus within the inner 
membrane. The signal sequence is cleaved and the passenger domain (light blue) moves through 
the C-terminal pore formation (green) to the extracellular environment. Foreign antigens of 
interest (blue) are depicted within the passenger domain.   
  
 This research involved developing B. avium as a universal poultry live vaccine platform for 
the expression of foreign antigens. It is hypothesized that B. avium can stably express foreign 
antigens, such as those from important poultry pathogens as Campylobacter jejuni, Clostridium 
perfringens, and  Hemorrhagic enteritis virus (HEV) (Table 1), to produce a strong immune 
response to multiple pathogens following intranasal vaccination. B. avium was chosen as the live 
vaccine platform due to its inability to infect humans, proven antigenicity, and limited toxicity to 
susceptible avian species (2, 9). Campylobacter jejuni is one of the leading causes of food-borne 
illnesses in humans, specifically cambylobacter gastroenteritis, in which contaminated poultry is 
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the primary source (10). CjaA, a substrate binding protein component of the ABC transport 
system, and FlaA, a flagellin protein, are two possible proteins of interest to be expressed. Some 
of the proteins secreted through C. jejuni flagella are found to be associated with virulence (11). 
The flagella proteins are highly conserved between Campylobacter species and the proteins are 
highly immunogenic in poultry, validating their potential use in a vaccine (10). CjaA also 
encodes a highly immunogenic protein conserved among Campylobacter species, which is 
necessary to be an effective vaccine (12). Immunization of chickens with a recombinant 
Salmonella vaccine strain expressing the C. jejuni cjaA gene has proven to be a successful 
candidate for vaccine delivery (12, 13). Poultry are a key reservoir for food borne infections, 
establishing the need for an effective vaccine.    
  
Table 1. Zoonotic diseases of poultry to which a new or improved vaccine is needed.  
Bacteria or 
Virus 
Susceptible 
poultry species 
 
Problem(s) with 
available vaccine(s) 
Promising antigen 
candidate(s) for use in 
subunit vaccines 
Chickens Turkeys 
Avian flu X X Viral propagation in 
tissue culture; re-
assortment 
H5 (14-16) 
Avian 
pneumovirus 
(APV) 
X X Viral propagation in 
tissue culture 
Small non-glycosylated 
hydrophobic protein (SH) 
(17-20) 
Chlamydophila 
psittaci 
 X None available 
Major OMPs (19, 20) 
Hemorrhagic 
enteritis virus 
(HEV) 
 X Viral propagation in 
spleen or tissue 
culture; 
immunosuppressive 
Hexon (w/ 100 kDa 
protein), Fiber knob (21-23) 
Avian hepatitis E 
virus 
X  None available Orf2 capsid (24-26) 
Campylobacter 
jejuni 
X  None available CjaA, Flagellin gene fspA1 
(10-13) 
Clostridium 
perfringens 
X X None available Alpha-toxin, NeTb (27, 28) 
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Methods 
Primer Design 
 A bioinformatics analysis of the potential delivery plasmid design consisted of the E. coli 
plasmid pCR 2.1 with the Baa1 autotransporter and the foreign antigen of interest inserted into 
the passenger domain of the autotransporter. A promoter region of 250bp upstream of the Baa1 
autotransporter was cloned into the plasmid construct in order to test the expression in a plasmid 
before moving the vaccine construct into the chromosome. Antigens known to elicit immune 
responses in poultry from C. jejuni, C. perfringens, and HEV, specifically flaA and cjaA of C. 
jejuni, were cloned into the passenger domain of the autotransporter gene. Alanine and histidine 
linkers were engineered into the construct as shown in Figure 2. Antibodies to a portion of the 
passenger domain are available against a predicted antigenic epitope, antibodies to the histidine 
epitope are commercially available, and antibodies to cjaA and flaA are available through 
collaborators. The design of the hypothetical plasmid construct is illustrated by the plasmid in 
Figure 3.     
 
Figure 2. Schematic of chimeric delivery plasmid. A,A’-cloning vector; B-signal sequence; 
C,C’-Baa1 passenger; D,D’-alanine linkers; E-histidine linker; F-foreign epitope DNA; G- 
portion of transfer domain of Baa1. Regions B/C and C’/G provide DNA for homologous 
recombination. 
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Figure 3. Schematic of modified pCR 2.1 plasmid with the Baa1 autotransporter and the foreign 
antigen of interest. 
 
Polymerase Chain Reaction 
 Three regions of the plasmid construct were amplified by Polymerase Chain Reaction (PCR). 
Region 1 consisted of the promoter region, signal sequence, and part of the passenger domain. 
Region 2 consisted of the foreign antigen of interest, flaA or cjaA. Region 3 consisted of part of 
the passenger domain and the transport domain. The regions were amplified using the primers 
listed in Tables 2 and 3 for flaA and cjaA, respectively. The final volume of the PCR mixture for 
regions 1 and 3 was 50μl, and it contained dH2O, 10X KOD buffer, 0.2mM dNTPs, 1 mM 
MgSO4, 200ng 197N B. avium DNA, 0.3µM forward primer, 0.3µM reverse primer, and 1 U/μl 
KOD Hot Start Polymerase. Samples were run with the following program: 2 minutes at 94°C, 
30 cycles of 15 seconds at 94°C, 30 seconds at 67°C, and 10 seconds at 68°C, and 2 minutes at 
68°C. The final volume of the PCR mixture for region 2 was 25 μl, and it contained dH2O, 
250ng M1 C. jejuni DNA, 0.4 μM forward primer, 0.4 μM reverse primer, and 1X Promega 
Master Mix. Samples were run with the following program: 2 minutes at 95°C, 30 cycles of 15 
12 
seconds at 95°C, 1 minute at 50°C, and 1 minute at 68°C, and 5 minutes at 68°C. The PCR 
product length was verified with gel electrophoresis. DNA samples were purified using Zymo 
Clean and Concentrator kit.  
 
Table 2. Primer design for flaA construct.  
Region 1 Forward GCGGGATCCGGAAAAATCCCAGCTCCCGG 
 Reverse CGGACCGGTGCCGCCACTGTTGACGGTGC 
Region 2 Forward GCGACCGGTGCGGCAGCGGCGGCACACCACCATCACCACCAT 
TTGGTTTCAGCTATCAATGC 
Reverse CGGTCGCGAAATGCCGCCGCTGCCGCTTGTAATAGTTTTAAAAC
AT 
Region 3 Forward GCGTCGCGACAGTTCGGTGCAGTTTCAAT 
Reverse CGGGAATTCTTAAGGCCTGTCTTGAGTTC 
 
 
Table 3. Primer design for cjaA construct.  
Region 1 Forward GCGGGATCCGGAAAAATCCCAGCTCCCGG 
Reverse CGGACCGGTGCCGCCACTGTTGACGGTGC 
Region 2 Forward GCGACCGGTGCGGCAGCGGCGGCACACCACCATCACCACCATA
TGAAAAAAATACTTCTAAG 
Reverse CGGTCGCGAAATGCCGCCGCTGCCGCAATTTTTCCACCTTCAAT
CA 
Region 3 Forward GCGTCGCGACAGTTCGGTGCAGTTTCAAT 
Reverse CGGGAATTCTTAAGGCCTGTCTTGAGTTC 
 
Restriction Enzyme Digest 
The volume of the restriction enzyme mixture was 50 μl, and it contained 1 μg DNA, 1X NEB 
buffer, 0.5 units NEB restriction enzyme, and up to 50 μl dH2O. The reaction was incubated at 
37°C for 1 hour. The restriction enzyme digest product length for the vector and insert was 
verified with gel electrophoresis.  
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Ligation and Transformation 
Ligations of the individual regions with the pCR 2.1 vector were performed using the TOPO TA 
Cloning Kit, with a vector to insert ratio of 1 to 4. Once the individual regions were ligated into 
their respective plasmid, these plasmids were ligated together using T4 DNA Ligase, with a 
vector to insert ratio of 1 to 3.  Transformations were performed using the TOPO TA Cloning 
Kit.  
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Results 
 Constructs of the Baa1 autotransporter with the foreign antigen of interest were assessed 
through bioinformatics analysis, including Basic Local Alignment Search Tool (BLAST) 
analysis, to confirm that the primer design was correct and that the genes were in frame and in 
the correct orientation (Figure 4). The hypothetical construct sequence, created using the 
software Gene Construction Kit, was searched through BLAST to confirm the presence of each 
of the domains, including the passenger and transport domains of the autotransporter and the 
foreign gene of interest. Within the construct of flaA, the domains that appeared were a 
transpeptidase, passenger, autotransport, and flagellin domain. Within the construct of cjaA, the 
domains that appeared were a transpeptidase, passenger, autotransport, and periplasmic binding 
protein domain.  
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Figure 4. BLAST analysis of Baa1 constructs. BLAST results show putative domains within the 
searched sequence. A-FlaA; B-CjaA. 
 
 
 Two approaches were taken to create the plasmid construct. The first approach involved 
amplifying the individual regions, cutting the regions with restriction enzymes, and ligating the 
regions together before inserting them into the E. coli plasmid pCR 2.1. PCR primer sets were 
designed for the three regions of the construct to be amplified, the promoter to the beginning of 
the foreign antigen in the passenger domain, the foreign antigen of interest, and the end of the 
foreign antigen in the passenger domain to the end of the transport domain (Figure 3). A product 
was produced for each of the regions with a size of 775bp, 912bp for flaA, and 1243bp, 
respectively (Figure 5). Restriction enzyme digests were performed using AgeI and NruI to ligate 
A 
 
 
 
 
 
 
 
 
B 
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the regions together. This approach was successful only in joining two of the fragments, regions 
1 and 2, rather than all three.  
 
Figure 5. Agarose gel electrophoresis of PCR amplified regions of Baa1 construct. Lane 1: 1kb 
Ladder; Lane 2: Region 1; Lane 3: Region 2 (flaA); Lane 4: Region 3. 
 
 
 The second approach involved inserting each individual region into the E. coli plasmid pCR 
2.1. Once each region was successfully inserted separately into pCR 2.1, a ligation was 
performed between two of the plasmids to join the promoter and transporter regions. The ligation 
product was transformed into E. coli and confirmed through sequencing. The promoter and 
transporter regions were cloned together and confirmed through restriction enzyme digest with 
AgeI in which one band was predicted to occur at 6kb (Figure 6). However, the clone containing 
the promoter region was difficult to grow. The E. coli grew more slowly at 37°C as well as 22°C 
and colonies appeared mucoid. The clone containing the promoter and transporter region 
10 kb 
6 kb 
4 kb 
3 kb 
2 kb 
1.5 kb 
1 kb 
 
 
0.5 kb  
1           2           3          4 
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appeared to be unstable since very few colonies contained both inserts. Putative clones that may 
contain flaA and cjaA with the promoter and transporter regions are currently being screened 
using biotin labeling (Dr. Kiran Nehra). 
 
Figure 6. Agarose gel electrophoresis of restriction enzyme digest of pCR 2.1 with promoter and 
transporter ligated regions of the Baa1 construct. Lane 1: 1kb Ladder; Lanes 2: pCR 2.1 with 
promoter and transporter regions digested with AgeI.  
 
 
 
 
 
 
 
 
1       2          
10 kb 
 
6 kb 
4 kb 
3 kb 
 
2 kb 
1.5 kb 
 
1 kb 
 
0.5 kb  
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Discussion 
 The development of a live-attenuated B. avium vaccine is necessary for controlling the 
emergence of zoonotic infections in poultry and improving the current vaccination methods. The 
vaccine will be developed to present a variety of foreign antigens derived from numerous 
pathogens with zoonotic potential. This method of vaccine development proves advantageous 
due to the low cost of vaccine production, the possible maintenance of the vaccine strain in a 
population of animals, the simultaneous delivery of bacterial antigens that act as immunological 
adjuvants, and the generation of distinctive serologic fingerprints in immunized animals (29-31). 
The use of a bacterial organism as a vaccine carrier over viral recombinant vaccines relies on 
minimal reactogenicity and maximal immunogenicity (31).  
 Many locations within the chromosome of B. avium could have been chosen for the insertion 
of heterologous antigens. Cell surface structures usually work well for live vaccines so the 
antigen can be presented at the surface. Some possible locations in B. avium that were considered 
were flagella structural genes, fimbrial structural genes, the HagB hemagglutinin, and the Baa1 
autotransporter. The current strategy using the Baa1 autotransporter is based on assumptions that 
have not been proven. The expression, secretion, and antigenic properties of this strategy have 
not been shown; however, these properties can only be tested by examining the cell surface 
structure’s potential use within the B. avium vaccine delivery system.  
 The Baa1 autotransporter system is well understood and its location for the insertion of 
foreign poultry antigens is likely to be successful (5). Many live bacterial vectors have been 
successfully used as antigen delivery systems, such as Salmonella spp., Shigella spp., 
Staphylococcus spp., and Bacillus anthracis (31). One successful delivery system involved using 
Salmonella enterica serovar Typhimurium, expressing the C. jejuni amino acid binding protein 
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CjaA. The delivery system significantly reduced the bacterial loads in turkeys and supported the 
potential use of CjaA-based vaccines for controlling C. jejuni in poultry (12, 13). Success of the 
efforts to use B. avium as a vaccine platform will allow for the delivery of any number of foreign 
antigens and respond to a number of poultry pathogen threats.   
 The two methods described in the results provide different approaches to construct the final 
plasmid of interest. The different approaches allow us to evaluate the best method for plasmid 
construction in order to create a successful plasmid with the foreign antigen of interest. Some 
difficulties were encountered during this project, such as the lack of success in PCR production 
of multiple fragments. Protocols have been modified to produce successful PCR products by 
altering the annealing temperature and polymerases. Another difficulty encountered was the 
negative effects of the promoter region on the host bacterium. The construct with the promoter 
region was difficult to grow and the construct with the promoter and transporter regions was not 
stable. The construct will be moved into a low copy number plasmid, such as pBBR1-MCS, 
since the use of low copy number vectors has improved the performance of bacterial strains as 
vaccine carriers (31). 
 Successful plasmid constructions will be transferred intact into the broad host range plasmid 
pBBR1-MCS. The chimeric pBBR1-MCS will be moved into B.avium Δbaa1 by conjugation. 
Expression will be confirmed through western blot analysis to insure that the fusion is effectively 
being transcribed and translated. Cell surface localization of the foreign epitopes will be assessed 
through fluorescent detection by microscopy. The effect on attachment to turkey tracheal rings as 
well as the toxicity to ciliated tissue cultures will also be evaluated.   
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